Plain-English translation of NCT04563520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a special blood test called a thrombin generation assay can help doctors personalize doses of a medicine called aPCC (activated prothrombin complex concentrate) — an emergency treatment for bleeding in people with hemophilia A who have developed antibodies against standard treatments. Right now, doctors use standard doses of this medication, but this study asks: can we use a blood test to find each person's ideal dose?
Some people with hemophilia A develop antibodies that block the standard bleeding treatment, making it harder to stop bleeds. A newer preventive medication called has helped many of these patients, but we still need a better way to choose the right dose of emergency medicine when they do bleed. This study could help doctors personalize treatment and improve safety.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic for one testing session. First, a blood sample will be taken to measure your baseline clotting response. Then you'll receive an infusion of the emergency medicine at a starter dose, and another blood sample will be taken 15–30 minutes later to see how your blood responded. Depending on those results, you may receive a second dose and have another blood sample taken. The entire visit focuses on measuring how your blood clots in response to this medicine, to help doctors understand your personalized dose needs.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States